Degenerate minigene library analysis enables identification of altered branch point utilization by mutant splicing factor 3B1 (SF3B1)

被引:5
|
作者
Gupta, Abhishek K. [1 ]
Murthy, Tushar [2 ]
Paul, Kiran, V [1 ]
Ramirez, Oscar [1 ]
Fisher, Joseph B. [3 ]
Rao, Sridhar [3 ]
Rosenberg, Alexander B. [4 ]
Seelig, Georg [5 ]
Minella, Alex C. [3 ]
Pillai, Manoj M. [1 ]
机构
[1] Yale Canc Ctr, Sect Hematol, New Haven, CT 06520 USA
[2] Northwestern Univ, Driskill Grad Program, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Bloodctr Wisconsin, Blood Res Inst, Milwaukee, WI 53233 USA
[4] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA
[5] Univ Washington, Paul G Allen Sch Comp Sci & Engn, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
MUTATIONS; MYELODYSPLASIA; SELECTION;
D O I
10.1093/nar/gky1161
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer-associated mutations of the core splicing factor 3 B1 (SF3B1) result in selection of novel 3splice sites (3SS), but precise molecular mechanisms of oncogenesis remain unclear. SF3B1 stabilizes the interaction between U2 snRNP and branch point (BP) on the pre-mRNA. It has hence been speculated that a change in BP selection is the basis for novel 3SS selection. Direct quantitative determination of BP utilization is however technically challenging. To define BP utilization by SF3B1-mutant spliceosomes, we used an overexpression approach in human cells as well as a complementary strategy using isogenic murine embryonic stem cells with monoallelic K700E mutations constructed via CRISPR/Cas9-based genome editing and a dual vector homology-directed repair methodology. A synthetic minigene library with degenerate regions in 3 intronic regions (3.4 million individual minigenes) was used to compare BP usage of SF3B1(K700E) and SF3B1(WT). Using this model, we show that SF3B1(K700E) spliceosomes utilize non-canonical sequence variants (at position -1 relative to BP adenosine) more frequently than wild-type spliceosomes. These predictions were confirmed using minigene splicing assays. Our results suggest a model of BP utilization by mutant SF3B1 wherein it is able to utilize non-consensus alternative BP sequences by stabilizing weaker U2-BP interactions.
引用
收藏
页码:970 / 980
页数:11
相关论文
共 50 条
  • [1] Splicing factor 3B1 hypomethylation is associated with altered SF3B1 transcript expression in older humans
    Holly, Alice C.
    Pilling, Luke C.
    Hernandez, Dena
    Lee, Benjamin P.
    Singleton, Andrew
    Ferrucci, Luigi
    Melzer, David
    Harries, Lorna W.
    MECHANISMS OF AGEING AND DEVELOPMENT, 2014, 135 : 50 - 56
  • [2] IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION
    Liberante, F.
    Lappin, K.
    Savage, K.
    Mills, K.
    HAEMATOLOGICA, 2016, 101 : 67 - 67
  • [3] Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated Erythropoiesis and a Stem Cell Disadvantage
    Obeng, Esther A.
    McConkey, Marie E.
    Campagna, Dean
    Schneider, Rebekka K.
    Chen, Michelle C.
    Schmidt, Paul J.
    Mullally, Ann
    Fleming, Mark D.
    Ebert, Benjamin L.
    BLOOD, 2014, 124 (21)
  • [4] SF3B1: from core splicing factor to oncogenic driver
    Bak-Gordon, Pedro
    Manley, James L.
    RNA, 2025, 31 (03) : 314 - 332
  • [5] Potential role of the splicing factor SF3B1 in epigenetic regulation
    Deliard, Sandra
    Okamoto, Yasuyuki
    Madzo, Jozef
    Jelinek, Jaroslav
    Issa, Jean-Pierre
    CANCER RESEARCH, 2017, 77
  • [6] A PROTAC targets splicing factor 3B1
    Gama-Brambila, Rodrigo A.
    Chen, Jie
    Zhou, Jun
    Tascher, Georg
    Munich, Christian
    Cheng, Xinlai
    CELL CHEMICAL BIOLOGY, 2021, 28 (11): : 1616 - +
  • [7] Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia
    Visconte, Valeria
    Adema, Vera
    Tiwari, Anand D.
    Kerr, Cassandra M.
    Awada, Hassan
    Przychodzen, Bartlomiej
    Noe, Allison
    Toth, Rachel
    Snider, Christina
    Parker, Yvonne
    Fedorov, Yuriy
    Adams, Drew
    Carraway, Hetty E.
    Advani, Anjali S.
    Kelly, Kevin R.
    Nawrocki, Steffan T.
    Carew, Jennifer S.
    Rogers, Heesun J.
    Lindner, Daniel J.
    Sekeres, Mikkael A.
    Phillips, James G.
    Maciejewski, Jaroslaw P.
    BLOOD, 2019, 134
  • [8] Mutant SF3B1 promotes malignancy in PDAC
    Simmler, Patrik
    Ioannidi, Eleonora I.
    Mengis, Tamara
    Marquart, Kim Fabiano
    Asawa, Simran
    Van-Lehmann, Kjong
    Kahles, Andre
    Thomas, Tinu
    Schwerdel, Cornelia
    Aceto, Nicola
    Ratsch, Gunnar
    Stoffel, Markus
    Schwank, Gerald
    ELIFE, 2023, 12
  • [9] The splicing factor SF3B1 is involved in brown adipocyte thermogenic activation
    Castella, Moises
    Mestres-Arenas, Alberto
    Gavalda-Navarro, Aleix
    Blasco-Roset, Albert
    Quesada-Lopez, Tania
    Romero-Carraminana, Ines
    Giralt, Marta
    Villarroya, Francesc
    Cereijo, Ruben
    BIOCHEMICAL PHARMACOLOGY, 2024, 220
  • [10] MicroRNA biogenesis is broadly disrupted by inhibition of the splicing factor SF3B1
    Velasco, Angela Downie Ruiz
    Parsons, Aimee L.
    Heatley, Matthew C.
    Martin, Athena R. G.
    Smart, Alfredo D.
    Shah, Niraj
    Jopling, Catherine L.
    NUCLEIC ACIDS RESEARCH, 2024, 52 (15) : 9210 - 9229